MEPRON is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Glaxosmithkline Llc. The primary component is Atovaquone.
Product ID | 0173-0665_05a331de-d581-4138-803d-61e14a00bb15 |
NDC | 0173-0665 |
Product Type | Human Prescription Drug |
Proprietary Name | MEPRON |
Generic Name | Atovaquone |
Dosage Form | Suspension |
Route of Administration | ORAL |
Marketing Start Date | 1995-02-28 |
Marketing Category | NDA / NDA |
Application Number | NDA020500 |
Labeler Name | GlaxoSmithKline LLC |
Substance Name | ATOVAQUONE |
Active Ingredient Strength | 750 mg/5mL |
Pharm Classes | Antimalarial [EPC],Antiprotozoal [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 1995-02-28 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA020500 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 1995-02-28 |
Ingredient | Strength |
---|---|
ATOVAQUONE | 750 mg/5mL |
SPL SET ID: | b426b6bf-f07e-4580-97ae-dfca1ddf5b8f |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0173-0547 | MEPRON | atovaquone |
0173-0665 | MEPRON | atovaquone |
0121-0888 | Atovaquone | Atovaquone |
0121-0898 | Atovaquone | Atovaquone |
0121-1796 | Atovaquone | Atovaquone |
0904-7064 | Atovaquone | Atovaquone |
16714-900 | atovaquone | atovaquone |
31722-629 | Atovaquone | Atovaquone |
50268-086 | Atovaquone | Atovaquone |
51407-642 | Atovaquone | Atovaquone |
60687-534 | Atovaquone | Atovaquone |
65162-693 | ATOVAQUONE | ATOVAQUONE |
66689-062 | Atovaquone | Atovaquone |
66993-062 | Atovaquone | atovaquone |
68180-282 | Atovaquone | Atovaquone |
10702-223 | Atovaquone Oral Suspension | Atovaquone |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
MEPRON 74256057 1769087 Live/Registered |
GLAXOSMITHKLINE LLC 1992-03-16 |
MEPRON 73431591 1304020 Live/Registered |
Degussa Aktiengesellschaft 1983-06-23 |